Myosin heavy chain 9 mRNA 3' untranslated region (MYH9 mRNA 3' UTR) (MYH9 mRNA 3' UTR)

The Myosin heavy chain 9 (MYH9) mRNA 3' untranslated region (3' UTR) is a critical regulatory segment of the transcript encoding non-muscle myosin heavy chain IIA (NMHC IIA) (UniProt: P35579). This region serves as a hub for post-transcriptional control, containing multiple binding sites for microRNAs such as miR-145, miR-506, and miR-647, which modulate mRNA stability and translational efficiency (PubMed: 21602814, 28651550). Biologically, the protein product of MYH9 is essential for cytokinesis, cell migration, and maintaining the structural integrity of cells like platelets and renal podocytes (NCBI Gene: 4627). Dysregulation of the MYH9 3' UTR, often through the loss of microRNA-mediated suppression, leads to protein overexpression that drives epithelial-mesenchymal transition (EMT) and metastasis in various cancers (PubMed: 25673441). Furthermore, mutations affecting the MYH9 gene can lead to MYH9-related disorders (MYH9-RD), characterized by macrothrombocytopenia and progressive renal failure (PubMed: 21131582). While no therapies targeting this specific UTR are currently FDA-approved, it is an active area of research for RNA-based therapeutics, including antisense oligonucleotides (ASOs) and microRNA mimics designed to restore normal expression levels. Potential safety concerns for targeting this region include the risk of inducing bleeding disorders or kidney damage due to the fundamental role of MYH9 in platelet and podocyte function.

Other names

MYH9 3' untranslated regionNon-muscle myosin heavy chain IIA mRNA 3' UTRNMHC IIA mRNA 3' UTRMYH9 3' UTR

RNA interference, antisense-mediated mRNA degradation, and translational inhibition via microRNA binding sites